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Effect of 4 years of growth hormone therapy in
children with Noonan syndrome in the American
Norditropin Studies: Web-Enabled Research
(ANSWER) ProgramW registry
Peter A Lee1*, Judith Ross2, John A Germak3 and Robert Gut3

Abstract
Background: Noonan syndrome (NS) is a genetic disorder characterized by phenotypic features, including facial
dysmorphology, cardiovascular anomalies, and short stature. Growth hormone (GH) has been approved by the
United States Food and Drug Administration for short stature in children with NS. The objective of this analysis was
to assess the height standard deviation score (HSDS) and change in HSDS (ΔHSDS) for up to 4 years (Y4) of GH
therapy in children with NS.
Methods: The American Norditropin Studies: Web-Enabled Research (ANSWER) ProgramW, a US-based registry,
collects long-term efficacy and safety information on patients treated with NorditropinW (somatropin rDNA origin,
Novo Nordisk A/S) at the discretion of participating physicians. A total of 120 children (90 boys, 30 girls) with NS,
naïve to previous GH treatment, were included in this analysis.
Results: The mean (SD) baseline age of subjects (n = 120) was 9.2 (3.8) years. Mean (SD) HSDS increased from –2.65
(0.73) at baseline to –1.32 (1.11) at Y4 (n = 17). Subjects showed continued increase in HSDS from baseline to Y4
without significant differences between genders at Y1 or Y2. The mean (SD) GH dose was 47 (11) mcg/kg/day at
baseline and 59 (16) mcg/kg/day at Y4. There was a negative correlation between baseline age and ΔHSDS at Y1
(R = –0.3156; P = 0.0055) and Y2 (R = –0.3394; P = 0.017). ΔHSDS at Y1 was significantly correlated with ΔHSDS at Y2
(n = 37; R = 0.8527, P < 0.0001) and Y3 (n = 20; R = 0.5145; P = 0.0203), but not Y4 (n = 12; R = 0.4066, P = 0.1896).
Conclusions: GH treatment-naïve patients with NS showed continued increases in HSDS during 4 years of treatment
with GH with no significant differences between genders up to 2 years. Baseline age was negatively correlated with
ΔHSDS at Y1 and Y2. Whether long-term therapy in NS results in continued increase in HSDS to adult height remains
to be investigated.
Trial registration: ClinicalTrials.gov NCT01009905
Keywords: Growth hormone, Noonan Syndrome, Somatropin, Short stature, Body height, Treatment outcome
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Introduction
Noonan syndrome (NS), a genetic disorder first described
by Noonan and Ehmke in 1963 [1], is characterized by
phenotypic features including facial dysmorphology, cardiovascular anomalies, and short stature [2]. Patients
with NS are typically born with appropriate size for gestational age, but reach median adult heights of only
162.5 cm and 152.7 cm for men and women, respectively, values that are approximately 2 SDS below the normal population [3]. While the etiology of short stature in
NS patients is not definitively known, growth hormone
(GH) therapy has been shown to improve growth rates
[4]. This improvement in both growth rates and adult
height is attributed, at least in part, to increased production of insulin-like growth factor 1 (IGF-1) [5]. Treatment with GH therapy has been shown to normalize
height standard deviation scores (HSDSs) during childhood for patients with NS [6,7].
Despite the successful gain in height associated with
GH therapy, response to treatment often varies. For
many patients, factors such as GH dose and age at start
of treatment may affect the outcome of GH therapy [8].
Furthermore, the success of GH therapy for patients with
NS may also be influenced by the genetic causes of the
disorder, although genetic mutations have not been identified in all patients with NS [9]. Currently identified genetic mutations explain approximately 60% of NS cases
[10]. Genetic mutations associated with the NS phenotype are involved in the Ras/MAPK (mitogen-activated
protein kinase) signal transduction pathway [10,11]. Several candidate genes involved in the Ras/MAPK signaling
pathway have been identified, with the protein tyrosine
phosphatase non-receptor type 11 gene (PTPN11) responsible for the greatest number of cases [10,11].
In 2007, the United States (US) Food and Drug Administration (FDA) approved the use of GH for short
stature in children with NS [12]. While this FDA approval is relatively recent, NS patients have been receiving GH therapy in clinical trials for a number of years,
and the results of these trials have been published
[2,4,7,13-18]. Since 2002, the American Norditropin
Studies: Web-Enabled Research (ANSWER) ProgramW
registry, which utilizes the enhanced research Webbased platform, NovoNetW, has been collecting longterm efficacy and safety data on patients treated with
NorditropinW (somatropin rDNA origin, Novo Nordisk
A/S) in the United States. The use of Norditropin in
patients within the ANSWER Program and participation
in the registry is at the discretion of the contributing
physician investigators and patient informed consent
and includes additional diagnostic conditions that warrant treatment with GH. Also, completeness of data concerning patients (e.g. background histories and physical
examination data, and additional findings from history
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and examination in addition to short stature, such as
cardiac and skeletal problems) may vary. Recently, data
from the ANSWER Program registry was used to assess
the impact of gender, puberty, and age on change in
height standard deviation scores (ΔHSDSs) following
2 years of GH treatment across many diagnostic categories, including GH deficiency, multiple pituitary hormone
deficiency, Turner syndrome, small for gestational age,
NS, and idiopathic short stature [19]. The study showed
that increase in HSDS could be achieved for all diagnostic categories, particularly when treatment was initiated
at an early age. In the present analysis, data from the
ANSWER Program registry are assessed to determine
HSDS and ΔHSDS during up to 4 years of GH therapy
in children with NS.

Objective and methods
The ANSWER Program is a US-based registry that has
collected long-term efficacy and safety information for
GH treatment-naïve and non-naïve patients treated with
Norditropin since 2002 (NCT01009905). Patients’ medical histories and physical examination data were entered
by participating physician investigators using the NovoNet
Web-based data entry tool. At the initial visit, study investigators collected baseline HSDS, weight, pretreatment bone
age, maximal stimulated serum GH concentration, and
serum IGF-1 concentrations. The data collected at followup clinical visits included GH dose/frequency, height,
weight, IGF-1 concentration, and bone age. Dosing was
determined by the treating physician.
Although both GH-naïve and non-naïve patients are
included in the ANSWER Program registry, data from
only GH-treatment-naïve patients (aged ≤ 18 years) with
NS were included in the current analysis. Potential subjects were excluded from the analysis if key variables had
baseline or subsequent values that were deemed physically or chronologically implausible. Cross-sectional data
from baseline, at year 1 (Y1), year 2 (Y2), year 3 (Y3),
and year 4 (Y4) were analyzed. Data at each post-baseline time point were collected within a ±3-month window. Baseline data were summarized, including gender,
age, HSDS, IGF-1 standard deviation score (IGF-1 SDS),
bone age, and maximal stimulated serum GH concentration. HSDS (z score) was calculated according to the
standard formulas provided by the Centers for Disease
Control and Prevention [20]. Target height was calculated using the following formula: [average of the parents’ heights] + 6.5 cm for males and [average of the
parents’ heights] − 6.5 cm for females. Target height SDS
is calculated according to the standard formulas provided by the CDC. HSDS corrected for target height,
[height SDS at each visit] − [target height SDS], was
determined annually. Change in HSDS (ΔHSDS) was
compared between gender groups using least squares
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means estimates from an analysis of covariance
(ANCOVA) model with gender as fixed effect and baseline HSDS value as a covariate. For analyses of age at
start of treatment, age ranges were defined to be <11 or
≥11 years of age for boys, and <10 or ≥10 years of age
for girls. These ages were chosen so that both younger
age categories would be comprised primarily of pre-pubertal individuals. Statistical comparisons of ΔHSDS between age groups stratified by gender were conducted
using t-tests. Linear regression was performed to identify
the relationship between ΔHSDS after 1 or 2 years of
GH treatment and age at start of treatment. Data following 3 or 4 years of treatment were not analyzed for logistic regression due to a limited number of patients. The
corresponding Pearson correlation coefficients (R) were
calculated along with the p values for testing their significance. Mean GH dose at each time point was summarized. Analyses were performed to evaluate (1)
whether ΔHSDS during the first year of therapy was predictive of ΔHSDS at later time points (linear regression
analysis), (2) whether baseline IGF-I or baseline IGF-I
SDS was predictive of ΔHSDS (linear regression analysis), and (3) whether ΔHSDS differed for GH-deficient
versus GH-sufficient patients (deficient GH status was
defined as GH peak at baseline <10; ΔHSDS was compared between groups using t-tests).

Results
Baseline demographics and patient disposition

The ANSWER Program registry contained information
for 120 children (90 boys and 30 girls) with NS. The
mean (SD) baseline age of all children with NS was 9.2
(3.8) years; the mean age for boys and girls was similar.
All patients in the younger age groups (ie, boys <11 years
and girls <10 years) were Tanner stage 1. Other characteristics are summarized in Table 1. Mean (SD) maximal
GH level was 11.7 (8.4) ng/ml (n = 34) with range of 0.8
to 39.3 ng/ml, while mean (SD) IGF-1 SDS of –3.0 (1.5)
indicated low IGF-1 levels (n = 73). The numbers of
patients that completed 1, 2, 3, and 4 years of treatment
were 76, 49, 31, and 17, respectively.
The effects of GH treatment on HSDS

The mean (SD) GH dose for the NS patients was 47 (11)
mcg/kg/day at baseline, 52 (12) mcg/kg/day after 1 year
of treatment, 49 (15) mcg/kg/day after 2 years of treatment, 54 (19) mcg/kg/day after 3 years of treatment, and
59 (16) mcg/kg/day after 4 years of treatment. Among
patients with 4 years of longitudinal data (n = 7), the
mean (SD) GH dose was 46 (3) mcg/kg/day at baseline,
53 (11) mcg/kg/day at 2 years, 57 (15) at 2 years, 58 (19)
mcg/kg/day at 3 years, and 63 (16) at 4 years. The overall effects of GH treatment on patients with NS are summarized in Figure 1. Cross-sectional data show that
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Table 1 Baseline Demographics
Characteristic

N

Mean (SD)

Median

Range

All subjects

120

9.2 (3.8)

9.6

1.6, 16.9

Boys

90

9.20 (4.09)

9.6

1.6, 16.9

Girls

30

9.24 (2.98)

9.6

2.8, 14.2

Age, years

HSDS
All subjects

120

–2.6 (0.7)

–2.6

–4.5, –1.2

Boys

90

–2.6 (0.74)

–2.44

–4.5, –1.2

Girls

30

–2.9 (0.67)

–2.88

–4.1, –1.7

Target HSDS

99

–0.3 (0.9)

–0.2

–3.8, 2.0

IGF-1 SDS

73

–3.0 (1.5)

–2.8

–8.2, 0.6

Bone age, years

93

7.7 (3.8)

7.8

0.5, 15.5

Maximal GH, ng/ml

34

11.7 (8.4)

10.0

0.8, 39.3

BMI

120

16.4 (2.0)

16.1

13.2, 26.9

Weight, kg

120

23.9 (9.4)

22.8

8.3, 51.6

BMI, body mass index; GH, growth hormone; HSDS, height standard deviation
score; SD, standard deviation.

mean (SD) HSDS increased from –2.65 (0.73) at baseline
to –1.32 (1.11) after 4 years of treatment (Figure 1A).
Mean (SD) HSDS corrected for target height, was –2.4
(1.02) at baseline, –2.0 (1.09) at Y1 (n = 64), –1.5 (1.22)
at Y2 (n = 42), –1.5 (1.24) at Y3 (n = 29), and –1.0 (1.50)
at Y4 (n = 14). Among the 7 patients for whom 4 years
of longitudinal data were available, mean (SD) HSDS
was –2.48 (0.76) at baseline, –2.29 (0.78) after 1 year of
treatment, –1.88 (1.08) after 2 years of treatment,–1.54
(1.23) after 3 years of treatment, and –1.22 (1.24) after
4 years of treatment (Figure 1B). Following 4 years of
GH treatment 12 of 17 patients (71%) achieved height
normal for age and gender (defined as HSDS > –2SD).
Patient gender did not significantly affect the outcome
of GH therapy for patients with NS. Mean (SD) HSDS
increased progressively from baseline for both boys and
girls. Comparisons from the ANCOVA model showed
no significant differences between boys and girls after 1
or 2 years treatment. On the contrary, patient age at
onset of therapy did affect outcome of GH therapy.
There was a significant negative correlation between
baseline age and change in HSDS after 1 year (n = 76;
correlation coefficient R = –0.3156; P = 0.0055) and
2 years of treatment (n = 49; R = –0.3394; P = 0.017) (Figure 2). Among boys, there was a significantly greater
ΔHSDS from baseline for the younger age group versus
the older age group after 1 and 2 years of treatment; no
significant differences were observed among girls at either time point, which may reflect the lower number of
female patients (Table 2).
Although the number of children with post-baseline
IGF-1 SDS data was limited, mean (SD) IGF-1 SDS
increased from a value of –2.96 (1.55) at baseline
(n = 73) to –1.35 (2.31) after 1 year of treatment (n = 17),
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A.

Baseline (n=120)

Year 1 (n=76)
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Year 2 (n=49)

Year 3 (n=31)

Year 4 (n=17)

3.00
2.00

0.75

1.00
HSDS

1.00

1.07

0.40

0.00
-1.00
-2.00
-3.00
-4.00

-2.65

-2.26

-1.96

-1.66

-1.32

Δ HSDS

Height SDS

B.
Baseline (n=7)

Year 1 (n=7)

Year 2 (n=7)

Year 3 (n=7)

Year 4 (n=7)

3.00
2.00

0.94

1.27

0.60

1.00
HSDS

0.19
0.00
-1.00
-2.00
-3.00
-2.48

-2.29

-1.88

-1.54

-1.22

-4.00
Height SDS

Δ HSDS

Figure 1 Mean HSDS Change at Year 1, Year 2, Year 3, and Year 4: (A) Cross-sectional Data and (B) Longitudinal Data. HSDS, height
standard deviation score.

–0.87 (2.79) after 2 years of treatment (n = 12),–0.02
(1.08) after 3 years of treatment (n = 7), and 0.22 (2.62)
after 4 years of treatment (n = 5). Mean (SD) weight
increased from baseline following 4 years of treatment,
whereas body mass index (BMI) remained stable (Figure 3). The small magnitude of the change in BMI suggests that increases in weight were proportional to
increases in height.
Several analyses were performed to examine early potential predictors of later response. ΔHSDS at Year 1 was
significantly correlated with ΔHSDS at Year 2 (n = 37;
R = 0.8527, P < 0.0001) and Year 3 (n = 20; R = 0.5145;
P = 0.0203), but not Year 4 (n = 12; R = 0.4066, P = 0.1896).
Neither baseline IGF-1 levels nor baseline IGF-1 SDS were
predictive of ΔHSDS (data not shown). GH-deficient
patients (n = 16) tended to have greater ΔHSDS than GHsufficient patients (n = 18); the difference was statistically
significant only at Year 2 (GH-deficient: n = 7, mean [SD]
ΔHSDS: 1.08 [0.66] vs GH-sufficient: n = 13, mean [(SD]
ΔHSDS: 0.40 [0.56]; P = 0.0266).

Discussion
Results from this 4-year analysis of GH therapy of NS
subjects from the ANSWER Program registry demonstrate an increase in HSDS over the course of treatment.

The mean HSDS (n = 120) at start of treatment was
–2.6. By the end of 3 years of GH therapy, mean HSDS
had increased to –1.66 (n = 31), and by the end of 4 years
to –1.32 (n = 17). This increase in mean HSDS is similar
to data from a clinical trial conducted by MacFarlane
et al., in which HSDS (SD) of NS patients (n = 23)
increased from –2.7 (0.4) at the start of GH therapy to
–1.9 (0.9) following 3 years of treatment [15]. Our findings are consistent with, and perhaps better than, results
from the National Cooperative Growth Study (NCGS),
which reported an increase in HSDS from –3.3 (0.9) at
baseline to –2.4 (1.1) at 3 years and –2.1 (1.2) at 4 years
(n = 42) [4], and to the Pharmacia & Upjohn International Growth Study (KIGS), which reported an increase from –2.9 (0.7) at baseline to approximately –2.3
at 4 years (n = 25) [14]. We also found an increase in
HSDS corrected for target height from –2.4 (1.02) at
baseline to –1.0 (1.50) at Y4.
Furthermore, for patients for whom longitudinal data
were available (n = 7), mean HSDS increased consistently
over the 4 years of treatment, indicating that GH therapy
of NS patients results in sustained growth over multiple
years of treatment. The yearly incremental change in
mean HSDS for these patients was 0.19, 0.41, 0.34, and
0.32 for Y1, Y2, Y3, and Y4 respectively. This trend of
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Year 1 HSDS Change from Baseline

A.
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3.0
2.5
2.0
1.5
1.0
0.5
0.0
–0.5
–1.0
–1.5
–2.0
0

1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18

Subject Age at Baseline

Year 2 HSDS Change from Baseline

B.

3.0
2.5
2.0
1.5
1.0
0.5
0.0
–0.5
–1.0
–1.5
–2.0
0

1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18

Subject Age at Baseline

Figure 2 Linear Regression of ΔHSDS at Year 1 and Year 2 on Baseline Age. At both (A) Year 1 (n = 76; correlation = -.3156; P = 0.0055) and
(B) Year 2 (n = 49; correlation = -.3394; P = 0.017), there was a significant negative correlation between ΔHSDS and baseline age (ie, ΔHSDS
decreased as baseline age increased).

sustained growth is consistent with a previous registrybased study conducted by Romano et al. In 1996, the
group analyzed data of 150 children with NS who were
enrolled in the NCGS [4]. For the 42 children in the
study who were monitored for at least 4 years of GH
Table 2 HSDS Change from Baseline Stratified by Age at
Treatment Start and by Gender
Boys
<11 years

≥11 years

Girls
<10 years

≥10 years

N Mean (SD) N Mean (SD) P value N Mean (SD) N Mean (SD) P value
Y1 32 0.53 (0.36) 22 0.24 (0.34) 0.0046 12 0.42 (0.51) 10 0.29 (0.38) 0.5159
Y2 25 0.94 (0.65) 13 0.47 (0.50) 0.0284 6 0.77 (0.55) 5 0.49 (0.67) 0.4726
Y3 16 0.92 (0.65) 10 1.01 (0.65) 0.7168 2 1.24 (0.33) 3 1.24 (0.45) 0.9968
Y4 6 1.15 (0.93) 8 0.90 (0.88) 0.6082 2 1.34 (0.78) 1

1.52 (—)

—

P values are for comparisons between age groups for each year.
HSDS, height standard deviation score; SD, standard deviation; Y1, year 1; Y2,
year 2; Y3, year 3; Y4, year 4.

therapy, yearly incremental change in mean HSDS was
0.5, 0.2, 0.2, and 0.3 for Y1, Y2, Y3, and Y4 of treatment,
respectively, with some patients exceeding their predicted height by the end of treatment..
However, even after 4 years of GH therapy, 29% (5/17)
of patients remained short for age and gender (as
defined by HSDS < –2 SD). Possible reasons for this
could include an innate resistance to GH therapy among
some with NS or advanced bone age/chronologic age at
treatment start. Without treatment, height in NS follows
the 3rd percentile during the first several years of life,
and then generally declines further at puberty, with
mean final height approximately 2 SDS below normal
limits [3,21].
The mean increase in HSDS was similar for boys and
girls in this study, suggesting that gender does not significantly affect the outcome of treatment. This trend
differs from previous clinical trial studies in which
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Baseline (n=120)

Year 1 (n=76)
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Year 2 (n=49)

Year 3 (n=31)

Year 4 (n=17)

70
44.7

60
32.5

50
27.2

40
30
20

36.8

16.4

16.6

17.3

17.4

18.9

23.9

10
0
Mean BMI (kg/m2)

Mean Weight (kg)

Figure 3 Mean BMI and Weight Change at Year 1, Year 2, Year 3, and Year 4 (Cross-sectional Data). BMI, body mass index.

gender was shown to affect the outcome of GH therapy
in patients with NS [6,16].
In contrast to what was observed in this analysis, previous registry-based studies have assessed the short- and
long-term effects of GH therapy in patients with NS and
found that the increase in height of NS patients treated
with GH therapy is highest after 1 year, but wanes in subsequent years of treatment. In 2001, Kirk et al. conducted
an analysis of NS patients involved in the KIGS study
[14]. The yearly incremental change in HSDS for these
patients waned significantly after 1 year of treatment.
Mean HSDS increased by 0.3 over the first year, but further increase was not observed over the next 4 years. A
similar trend was observed by Raaijmakers, et al., who
analyzed the growth response in 402 NS patients enrolled
in the KIGS database who were treated with GH therapy
[18]. After 1 year of treatment, mean HSDS increased by
0.54, but the incremental increases were significantly
lower (0.13 and 0.13) following years 2 and 3 of GH therapy. Finally, in the clinical trial conducted by MacFarlane
et al., ΔHSDS was 0.5 during the first year of treatment,
but the yearly incremental increase in mean HSDS
dropped to 0.1 and 0.2 for the second and third years of
treatment, respectively. It was confirmed in the MacFarlane clinical trial that the lower incremental increase in
HSDS for years 2 and 3 of treatment could not be attributed to reduced growth rate caused by non-adherence to
therapy [15]. Potential explanations for waning growth
may be related to older age at treatment onset, GH sufficiency status, GH dosage, and the presence of other genetic findings specific to NS. The presence of a specific
mutation may be a factor in the response to GH treatment, although the type of mutation does not necessarily
correlate with the severity of short stature or the patient’s
response to GH therapy [16,22-25]. In the current study,
the incremental gain in HSDS among the 7 patients for
whom longitudinal data were available was lowest during
Year 1. The mean GH dose among these patients
increased each year, which may explain, in part, why the
incremental gains were higher after Year 1.

The mean (SD) weight determined for the patients enrolled in the ANSWER Program registry increased from
23.9 (9.4) kg at baseline to 44.7 (15.9) kg following 4 years
of treatment, whereas body mass index (BMI) remained
stable. The small magnitude of the change in BMI suggests that increases in weight were proportional to
increases in height, indicating that GH therapy for NS
patients did not significantly impact body composition in
ways unrelated to linear growth. Although the number of
children with post-baseline IGF-1 SDS data was limited,
analysis of the available data showed that mean (SD)
IGF-1 SDS increased. Previous studies have indicated a
positive linear relationship between the change in IGF-1
and ΔHSDS for patients undergoing GH treatment [26].
In addition to sustained growth over the course of GH
treatment, and a positive correlation between ΔHSDS at
Year 1 and ΔHSDS at Years 2 and 3, analysis of data
from boys and girls in the ANSWER Program registry
also showed that a negative correlation exists between
the age at the start of treatment and ΔHSDS (Figure 2).
That is, ΔHSDS decreased as age at initiation of treatment increased. In an analysis using age 11 as a cutoff
for younger versus older age, boys who began treatment
before the age of 11 years showed a mean ΔHSDS of
0.53 after 1 year of treatment and 0.94 after 2 years
(Table 2). On the other hand, when treatment was
initiated for boys at an age greater than 11 years, mean
ΔHSDS was only 0.24 after 1 year (P = 0.046) and 0.47
after 2 years (P = 0.0284). The same trend was observed
for girls in this study, although differences were not statistically significant. Although the age cut-offs of 11 years
for boys and 10 years for girls did correspond to baseline
pubertal stage (ie, all patients in the younger age groups
were pre-pubertal), the relative contribution of the accelerated growth rate during the pubertal growth spurt is
unclear. A similar pattern was observed by Romano
et al. in data from the NCGS [7], which showed that
greater near adult height (NAH) for NS patients was
associated with earlier initiation and longer duration of
GH therapy.
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These results emphasize the importance of early diagnosis and initiation of therapy for optimal height outcomes. However, diagnosing NS is a difficult task, even
for many specialists, due to the fact that it is primarily
based on clinical features. Therefore, the Noonan Syndrome Support Group recently coordinated a conference
comprised of professionals with extensive knowledge of
various aspects of the disease to develop guidelines for
the diagnosis and management of the disorder [10].
These guidelines provide pediatricians and other healthcare professionals with a comprehensive description of
genetic factors associated with NS and key clinical features of the disorder.
One limitation of the current study is the lack of data
regarding the underlying genetic defect, particularly the
presence or absence of the PTPN11 mutation, responsible for causing NS in these patients. Nonetheless, this
analysis provides valuable information, such as expectations for treatment outcomes and the potential to
optimize growth by initiating GH treatment early, which
can help to guide clinicians who treat patients with NS.
In conclusion, this analysis of the ANSWER Program
registry shows that continued increase in HSDS after
4 years of treatment with GH could be achieved in GHnaïve subjects with NS, with no significant differences in
treatment outcome between genders at years 1 and 2.
The data also show that baseline age was negatively corty
related with ΔHSDS following 1 and 2 years of treatment.
Whether longer-term therapy will have a beneficial effect
on adult height remains to be investigated.
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